ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

Hemophilia and Rare Bleeding Disorders » Novel Biotherapeutics in Hemophilia

Theme Navigation

  • ISTH 2021 Congress
    • Hemophilia and Rare Bleeding Disorders
      • Novel Biotherapeutics in Hemophilia

Abstract Number: OC 32.1

Ex vivo Assessment of the Importance of Activated Factor IX (FIXa) Levels in the Procoagulant Effect of Recombinant FIX Concentrates in Emicizumab-treated Patients

E.G Arias-Salgado1, E. Monzón Manzano1, P. Acuña1, I. Fernández-Bello1, S. García Barcenilla1, M.T. Álvarez Román1, M. Martín1, M.I. Rivas Pollmar1, T. Cebanu1, E. González Zorrilla1, N. Butta1, V. Jiménez-Yuste1,2

Abstract Number: OC 48.1

A Blood Coagulation Factor IX Variant that Functions Independently of Factor VIII Mitigates the Hemophilia A Phenotype in Patient Plasma

V.J. Strijbis1, L.G. Romano2, K.L. Cheung1, Y.P. Liu3, A.C. McCreary3, F.W. Leebeek2, M.H. Bos1

Abstract Number: PB0682

A Systematic Review on the Pharmacokinetics and Associated Pharmacodynamics of Emicizumab in Humans

A. Donners1, C. Rademaker1, L. Bevers1, A. Huitema1,2,3, R. Schutgens1, A. Egberts1,4, K. Fischer1

Abstract Number: PB0675

Administration of fVIII Protein through Human Placental Cells Reduces the Risk of an Antibody Response in Juvenile Sheep

B. Trevisan1, M. Rodriguez1, S. George1, J. Shields2, S. Lankford1, R. Combs3, M. Gautreaux4, J. Owen3, A. Atala1, C.B. Doering2, H.T. Spencer2, C.D. Porada1, MG. Almeida-Porada1

Abstract Number: LPB0116

An Accurate and Simple Liquid Chromatography Tandem Mass-spectrometric Method for the Quantification of Emicizumab in People with Hemophilia A

A. Donners1, L. Gerencsér1, K. van der Elst1, K. Fischer1, R. Urbanus1, M. El Amrani1

Abstract Number: PB0678

Cost-effectiveness Analysis of the Brazilian Immune Tolerance Induction Protocol with Recombinant Factor VIII and Prophylaxis with Bypassing Agents or Emicizumab

R.M. Camelo1, S.M. Rezende1, J. Álvares-Teodoro2

Abstract Number: PB0686

Do New Therapies alter the Treatment of Hemophilia Patients?

H. Duda1, B. Haschberger1, J. Hesse1, H. Windecker1, A. Hilger1, C. Keipert1

Abstract Number: PB0684

Emi and Me: The Real-world Impact of Emicizumab on the Lives of People with Haemophilia A with Inhibitors and their Families

S. Fletcher1, M. Holland2, K. Jenner2, K. Khair2

Abstract Number: PB0681

Emicizumab Assays: One Stage vs. Chromogenic Stage Assay

M. Stuart1, D. Chen1, R. Pruthi1

Abstract Number: OC 49.2

Emicizumab: Will it Suffice for Bone Metabolism?

M. Manco-Johnson1, N. Briones1, A. Tran1, D. Thornhill1, C. Baird1, L. Jacobson1, B. Warren1, S. Kuldanek1, D. Ambruso1, G. Karsenty2

Abstract Number: PB0679

Measuring the Chromogenic FVIII Mimetic Activity of the New Bispecific Antibody, Mim8, in Artificially Spiked Severe Haemophilia A Plasma

A. Bowyer1, M. Ezban2, S. Kitchen1

Abstract Number: PB0680

Measuring the FVIII Mimetic Activity of the New Bispecific Antibody, Mim8, in Severe Haemophilia A Plasma Using APTT and One-stage FVIII Assays

A. Bowyer1, M. Ezban2, S. Kitchen1

Abstract Number: OC 48.4

Orally Delivered Factor VIII Restores Hemostasis in a Hemophilia A Dog

M.A. Hashim1, A. Yamaguchi1, A.T. Vo1, A.K. Dhalla1, B. Syed1, L.C. Fung1, V. Salgotra1, A. Dasari1, G. Schrenk2, O. Zoechling2, D. Sexton3, G. Allen3, C.T. Long4, E.P. Merricks4, M. Imran1, T.C. Nichols4

Abstract Number: PB0677

Real-world Experience of Emicizumab Treatment Using Entire Vials Only

K. Fischer1, A.A. Donners1, R.T Urbanus1, I.C. Kremer Hovinga1, L.F. van Vulpen1, P.R van der Valk1, K.P. van Galen1, N. Uitslager1, R.E. Schutgens1

Abstract Number: OC 08.4

Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database

M.E. Mancuso1, P. Chelle2, E. Iserman3, T. Matthew3, A. Keepanasseril3, A. Edginton2, A. Iorio3,4, WAPPS-Hemo Investigators

Abstract Number: PB0687

Successful Experience of Emicizumab Prophylaxis in a Child with Severe Hemophilia A and Inhibitor without Previous Immune Tolerance Induction

R.M. Camelo1, M. Palis2, M.A.F. de Cerqueira2, N. Dantas-Silva3, J. Álvares-Teodoro4

Abstract Number: PB0676

Tailoring the Effect of Antithrombin-targeting Therapy in Hemophilia A Using in Silico Thrombin Generation

R. de Laat-Kremers1, M. Ninivaggi1, I. van Moort2, M. de Maat2, B. de Laat1

Abstract Number: LPB0117

The Association of Emicizumab and rFVIIa for Major Orthopaedic Surgery

C. Carulli1, S. Linari2, L. Pieri2, G. Castaman2

Abstract Number: PB0674

The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood

M. Ezban1, K. Jensen1, J. Lund1

Abstract Number: OC 48.3

Therapeutic Knockdown of Plasminogen with siRNA in Hemophilia A and von Willebrand disease Mouse Models

P. Batty1, A. Strilchuk2, K. Nesbitt1, A. Yong2, D. Lillicrap1, C. Kastrup2

  • 1
  • 2
  • Next Page »

« View all themes from the ISTH 2021 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley